Protein regulation in multiple myeloma

多发性骨髓瘤中的蛋白质调控

基本信息

项目摘要

A recent publication from our group demonstrated that the induction of genes encoding effectors of the SUMOylation pathway correlated with decreased MM patient survival. Preliminary data suggest that genes from this pathway not only correlate with response to bortezomib in patients with relapsed MM, but also define a subset of patients at initial diagnosis. Therefore, we seek to further investigate the role of protein regulation by the SUMOylation pathway in myelomagenesis. SPECIFIC AIM 1: to investigate whether gene expression of selective E3s are induced in MM patient samples and correlated with resistance to bortezomib-based therapy. We will examine the gene expression profiles generated from patients on the CREST and APEX clinical trials. Preliminary data suggests that RNF4, an E3 that recognizes poly-SUMOylated proteins for proteasomal degradation, is significantly more highly expressed in MM malignant plasma cells compared to normal plasma cells. Moreover, RNF4 and other components of the SUMOylation, Ubiquitination and Proteasome pathways may be induced in MM patients that did not respond to bortezomib. We will further interrogate the role of RNF4 in protein regulation and resistance to bortezomib in MM cell lines. Specifically, we will both over-express and knock down RNF4 in MM cell lines and examine the cellular effects of treatment with bortezomib. SPECIFIC AIM 2: to expand the biomarker profiles to genes in the SUMO, Ubiqutin and proteasome subunit families in order to better identify subpopulations of patients more likely to respond to proteasome-directed therapy and identify new targets for therapeutic intervention. We will include at least 10 genes from each family of functionally related genes and compare their predictive values to that of clinical parameters such as age, B2-microglobulin, C-reactive protein and albumin. We will also investigate the individual correlations with overall survival after bortezomib treatment. We will also generate bortezomib-resistant MM cell lines in the laboratory and quantify the expression of these genes in the resistant cell lines compared to the parental bortezomib-sensitive cell lines.
我们小组最近发表的一篇文章表明,诱导编码SUMOylation通路效应子的基因与MM患者生存率降低相关。初步数据表明,来自该途径的基因不仅与复发性MM患者对硼替佐米的反应相关,而且在初次诊断时定义了一部分患者。因此,我们寻求进一步研究SUMOylation途径在骨髓瘤形成中的蛋白调控作用。特异性目的1:探讨选择性E3s基因表达是否在MM患者样本中被诱导,并与对硼替佐米治疗的耐药相关。我们将检查CREST和APEX临床试验患者的基因表达谱。初步数据表明,与正常浆细胞相比,RNF4在MM恶性浆细胞中的表达明显更高,RNF4是一种识别多sumoylated蛋白进行蛋白酶体降解的E3。此外,在对硼替佐米无反应的MM患者中,RNF4和sumo化、泛素化和蛋白酶体途径的其他组分可能被诱导。我们将进一步探究RNF4在MM细胞系中蛋白调控和对硼替佐米的抗性中的作用。具体来说,我们将在MM细胞系中过表达和敲低RNF4,并检测硼替佐米治疗的细胞效应。具体目标2:将生物标志物谱扩展到SUMO、Ubiqutin和蛋白酶体亚基家族的基因,以便更好地识别更可能对蛋白酶体定向治疗有反应的患者亚群,并确定治疗干预的新靶点。我们将包括来自每个功能相关基因家族的至少10个基因,并将其与临床参数(如年龄、b2微球蛋白、c反应蛋白和白蛋白)的预测值进行比较。我们还将研究硼替佐米治疗后个体与总生存率的相关性。我们还将在实验室中产生耐硼替佐米MM细胞系,并量化这些基因在耐药细胞系中与亲本硼替佐米敏感细胞系的表达。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christina Annunziata其他文献

Christina Annunziata的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christina Annunziata', 18)}}的其他基金

Clinical trials in womens cancers
女性癌症的临床试验
  • 批准号:
    10926247
  • 财政年份:
  • 资助金额:
    $ 9.31万
  • 项目类别:
Nuclear Factor-kappaB in Ovarian Cancer
卵巢癌中的核因子-kappaB
  • 批准号:
    10926118
  • 财政年份:
  • 资助金额:
    $ 9.31万
  • 项目类别:
Molecular characterization of endometrial cancer
子宫内膜癌的分子特征
  • 批准号:
    8157760
  • 财政年份:
  • 资助金额:
    $ 9.31万
  • 项目类别:
Immune cell control of ovarian cancer
卵巢癌的免疫细胞控制
  • 批准号:
    10486968
  • 财政年份:
  • 资助金额:
    $ 9.31万
  • 项目类别:
Nuclear Factor-kappaB in Ovarian Cancer
卵巢癌中的核因子-kappaB
  • 批准号:
    7965997
  • 财政年份:
  • 资助金额:
    $ 9.31万
  • 项目类别:
Molecular characterization of endometrial cancer
子宫内膜癌的分子特征
  • 批准号:
    8763450
  • 财政年份:
  • 资助金额:
    $ 9.31万
  • 项目类别:
Nuclear Factor-kappaB in Ovarian Cancer
卵巢癌中的核因子-kappaB
  • 批准号:
    8763324
  • 财政年份:
  • 资助金额:
    $ 9.31万
  • 项目类别:
Nuclear Factor-kappaB in Ovarian Cancer
卵巢癌中的核因子-kappaB
  • 批准号:
    8552955
  • 财政年份:
  • 资助金额:
    $ 9.31万
  • 项目类别:
Clinical trials in womens cancers
女性癌症的临床试验
  • 批准号:
    8938205
  • 财政年份:
  • 资助金额:
    $ 9.31万
  • 项目类别:
Clinical trials in womens cancers
女性癌症的临床试验
  • 批准号:
    9556639
  • 财政年份:
  • 资助金额:
    $ 9.31万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 9.31万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 9.31万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.31万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.31万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 9.31万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.31万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 9.31万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 9.31万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 9.31万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.31万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了